⚠️ Risk — Part 3: How Pharma, Media, and Regulators Use Risk Framing to Steer the Narrative
⚠️ Risk — The Numbers They Don’t Want You to Understand First, an apology for taking so long to publish the next part. Things with our outlets are doing so well that we are experiencing a lot of growing pains along the way... namely in staffing. We are doing the best we can and appreciate the patience. If Parts 1 & 2 showed you how the math gets manipulated, Part 3 shows you who benefits from it — and how the peptide world got dragged into a narrative war it didn’t even know it was in. Peptides sit at the intersection of three powerful agendas: - Pharma, which frames anything “unapproved” as dangerous - Media, which monetizes fear - Regulators, who use exaggerated risk to justify policy action Each group uses relative risk framing as its main weapon. Let’s break it down. 💊 1. The Pharma Playbook: “Unapproved = Unsafe” Here’s the trick: Pharma never has to prove a peptide is dangerous. They just have to make you feel like it’s dangerous. They do this by: - Highlighting small relative risks while ignoring absolute data - Citing mechanism-level “theoretical dangers” - Calling anything non-FDA-approved “high risk” - Funding or amplifying studies with dramatic hazard ratios - Using PR firms to push the “safety concern” narrative to journalists Meanwhile — and this is the part the public never hears — many approved therapeutics rely on the exact same biological pathways peptides modulate. Growth hormone signaling. Melanocortin receptors. Angiogenesis. Cell healing pathways. Metabolic regulation. Same biology. Different branding. 📰 2. The Media Incentive: Fear = Clicks Peptide articles follow the same template: - Step 1: Use a vivid case. - Step 2: Add a theoretical mechanism. - Step 3: Insert “may increase risk” language. - Step 4: Inflate using relative risk. - Step 5: End with a safety appeal: “Experts warn…” Media doesn’t need evidence. It needs engagement. A headline like: “Peptide X Doubles Risk of Dangerous Condition” will always outperform: